Orencia (Systemic Lupus Erythematosus and Lupus Nephritis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 15
3.2 Prognosis 16
3.3 Quality of Life 16
3.4 Symptoms 17
4 Disease Management 18
4.1 Diagnosis Overview 18
4.1.1 SLE Diagnosis 18
4.1.2 LN Diagnosis 21
4.2 Treatment Overview 23
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 Unmet Needs 30
6.2.1 Efficacious Treatments with Reduced Side Effects 30
6.2.2 Management of LN 32
6.2.3 Improvement in Patients’ Mortality 33
6.2.4 Management of Lupus Comorbidities 33
6.2.5 Sensitive and Reliable Biomarkers 34
6.2.6 Physicians’ Education and Public Awareness of SLE 35
6.2.7 Unmet Needs Gap Analysis 35
6.3 Opportunities 36
6.3.1 Efficacious and Safe Therapies 36
6.3.2 Therapies Targeting LN Patients 37
6.3.3 Treatments for Common Lupus Comorbidities 38
6.3.4 Discovery of Biomarkers 38
7 Pipeline Assessment 39
7.1 Overview 39
7.2 Promising Drugs in Clinical Development 40
8 Orencia (abatacept) 43
8.1 Overview 43
8.2 Efficacy 44
8.3 Safety 46
8.4 Dosing and Formulation 46
8.5 Potential Clinical Positioning 46
8.6 Potential Commercial Positioning 46
8.7 Pricing and Reimbursement 47
8.8 SWOT Analysis 47
8.9 Forecast 48
9 Appendix 50
9.1 Bibliography 50
9.2 Abbreviations 52
9.3 Methodology 54
9.4 Forecasting Methodology 54
9.4.1 Diagnosed SLE and LN Patients 54
9.4.2 Percent Drug-Treated Patients 55
9.4.3 General Pricing Assumptions 55
9.4.4 Generic Erosion 56
9.4.5 Pricing of Pipeline Agents 56
9.5 Physicians and Specialists Included in this Study 56
9.6 Primary Research – Prescriber Survey 58
9.7 About the Authors 59
9.7.1 Analysts 59
9.7.2 Global Head of Healthcare 60
9.8 About GlobalData 61
9.9 Disclaimer 61